Clinical consequences of Aspergillus disease in cystic fibrosis
| ISRCTN | ISRCTN16364688 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN16364688 |
| Integrated Research Application System (IRAS) | 232722 |
| Protocol serial number | IRAS232722 |
| Sponsor | Wythenshawe Hospital, Manchester Univaersity NHS Foundation Trust |
| Funder | Manchester Adult Cystic Fibrosis Centre |
- Submission date
- 21/11/2017
- Registration date
- 22/03/2018
- Last edited
- 22/03/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Plain English summary of protocol
Background and study aims
Cystic fibrosis (CF) is a genetic disease which affects the whole body, but respiratory/lung disease is the most prominent problem. Patients with CF are colonised by different bacteria and fungi which can cause lung disease of varying severity, and one of these bugs is the fungus Aspergillus. Aspergillus is a fungus that is found in the environment, and while people with normal lungs and immune system are not affected by the fungus, CF patient's lungs are particularly vulnerable to infection. There are four potential types of Aspergillus disease in CF which have been recently described in a previous study and the health consequences of these types of disease are not well known in comparison to each other. The aim of this study is to look back at the patients involved in the original study that proposed the four types of Aspergillus disease and investigate the decline in health and survival outcomes for each type. Patients may change disease type over time, therefore patients from the previous study are re-tested and re-diagnosed as an Aspergillus disease type to investigate this. As Aspergillus is found in the environment the levels of Aspergillus found in the air both in the CF unit and in patient's homes are measured using environmental sampling to understand more about the risks of acquiring Aspergillus lung disease, and the effects of ventilation in potentially reducing environmental levels.
Who can participate?
Cystic fibrosis patients aged over 18 who were involved in the previous study to classify Aspergillus disease are approached to be involved in this study
What does the study involve?
Participants have a blood sample and a sputum sample taken to re-test for Aspergillus disease type. These tests are done as part of a CF patient's normal care and do not require an extra trip to the hospital. Patients are also given the option to have their home air tested for the presence of Aspergillus, and this is done by the doctor at a home visit of less than 30 minutes.
What are the possible benefits and risks of participating?
The benefit of taking part in this study is to help increase knowledge of Aspergillus disease in CF. No risks are foreseen.
Where is the study run from?
The Manchester Adult Cystic Fibrosis Centre in Wythenshawe Hospital in Manchester (UK)
When is the study starting and how long is it expected to run for?
September 2016 to September 2018
Who is funding the study?
Manchester Adult Cystic Fibrosis Centre (UK)
Who is the main contact?
Dr Lisa Collier
lisa.collier@mft.nhs.uk
Contact information
Scientific
Manchester Adult Cystic Fibrosis Centre
Manchester University NHS Foundation Trust
Wythenshawe Hospital
Southmoor Road
Manchester
M23 9LT
United Kingdom
| Phone | +44 (0)161 291 4321 |
|---|---|
| lisa.collier@mft.nhs.uk |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Single-centre longitudinal cohort study |
| Secondary study design | Longitudinal study |
| Study type | Participant information sheet |
| Scientific title | Clinical consequences of Aspergillus colonisation and disease in cystic fibrosis and the role of environment in acquisition and infection |
| Study acronym | AspCF |
| Study objectives | Aspergillus disease in cystic fibrosis can be classified into four phenotypes (1. No disease, 2. Allergic bronchopulmonary aspergillosis, 3. Aspergillus sensitised, 4. Aspergillus bronchitis). The diagnostic criteria for these classifications was outlined by Baxter et al. 2013 and the same patient cohort used in this study will be followed up to 9 years to review clinical consequences of each class of disease, survival outcomes, and be prospectively re-classified to ascertain whether patient change disease class over time. |
| Ethics approval(s) | North West - Liverpool East - submission pending |
| Health condition(s) or problem(s) studied | Pulmonary Aspergillus disease in patients with cystic fibrosis |
| Intervention | Patients involved in the previous trial which classified aspergillus disease by phenotype (REC ref: 07/Q1403/70) will followed up to the current day to monitor clinical outcomes and clinical decline, in order to compare the severity of each phenotype. The surviving patients will be approached to consent to reclassification of Aspergillus disease by means of blood test for Aspergillus IgE, Aspergillus IgG, Total IgE and Galactomannan, along with a sputum sample for Aspergillus. These tests form regular follow up of these patients and will not require hospital appointments above their usual outpatient follow up. They will also be asked if they will consent to environmental air sampling of their home either by drop plates being sent to them and/or microbial air sampling. Patients can choose to consent to either or both re-classification and environmental sampling. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Diagnosis of Aspergillus phenotype by means of blood test for Aspergillus IgE, Aspergillus IgG, Total IgE and Galactomannan, along with a sputum sample for Aspergillus, both at baseline . This is compared to previous phenotype diagnosed in study REC ref: 07/Q1403/70 to establish if change in disease class has occurred |
| Key secondary outcome measure(s) |
Aspergillus/fungal exposure at a patient's residence, determined by environmental sampling at baseline. This will supplement data collected as part of air quality surveys undertaken in the cystic fibrosis unit, both in inpatient and outpatient areas |
| Completion date | 30/09/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 110 |
| Key inclusion criteria | All patients will have taken part in study REC ref: 07/Q1403/70 between 2008-2011 (number = 129). Surviving patients who have not received a lung transplant or moved away from the unit since that time will be eligible for prospective reclassification of Aspergillus disease. All 129 patients will be followed up for retrospective data. 1. Cystic fibrosis patients > 18 years old, both male and female 2. Patients who have taken part in study REC ref: 07/Q1403/70 3. Patients eligible for reclassification of Aspergillus disease if not undergone lung transplantation or not moved away from area |
| Key exclusion criteria | 1. Non cystic fibrosis patients 2. Patients not involved in study REC reference number 07/Q1403/70 3. Patients who have undergone lung transplantation 4. Patients who have moved away from the area during follow-up time from original study |
| Date of first enrolment | 01/01/2018 |
| Date of final enrolment | 30/09/2018 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Southmoor Road
Wythenshawe
Manchester
M23 9LT
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Andrew Jones. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
